Vir Biotechnology, Inc.

dAIsY

Proprietary AI and machine learning-driven antibody optimization platform for engineering therapeutic candidates including TCEs and mAbs for infectious diseases and oncology. Used to optimize potency, resistance, pharmacokinetics, and manufacturability.

PRO-XTEN · Sanofi

Universal protease-activated masking technology platform licensed from Sanofi (Amunix) for oncology and infectious diseases. Attaches masks to TCEs or cytokines via protease-cleavable linkers; masks are cleaved in the tumor microenvironment to selectively activate drug, improving safety and therapeutic index.

Targets: CD3, PSMA, HER2, EGFR

PRO-XTEN · Amunix Pharmaceuticals (a Sanofi company)

Dual-masking technology that keeps T-cell engagers inactive until they reach the tumor microenvironment, where tumor-specific proteases cleave the mask and activate the TCE; designed to reduce systemic toxicity and extend half-life; applied across oncology and infectious disease programs

PRO-XTEN · Amunix Pharmaceuticals (Sanofi)

Dual-masking platform for T-cell engagers (TCEs) designed to keep TCEs inactive until reaching the tumor microenvironment, reducing off-target effects and improving therapeutic index; Vir Biotechnology retains exclusive rights for oncology and infectious disease; PRO-XTEN is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company

Targets: PSMA, CD3, HER2, EGFR

PRO-XTEN · Amunix Pharmaceuticals

Dual-masking T-cell engager platform technology using XTEN polypeptide masks that keep TCEs inactive until tumor-specific proteases cleave the mask in the tumor microenvironment; applied across oncology and infectious disease; licensed from Amunix Pharmaceuticals (a Sanofi company), with Vir holding exclusive rights for oncology and infectious disease

Targets: PSMA, HER2, EGFR

PRO-XTEN · Sanofi (via Amunix Pharmaceuticals)

Dual-masking platform technology that keeps T-cell engagers inactive until reaching the tumor microenvironment, reducing off-target effects and improving therapeutic index; focus on solid tumor indications and infectious diseases